Exelixis, Inc.

    Jurisdiction
    United States
    ISIN
    US30161Q1040 (EXEL)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    €84.44 153.5% undervalued
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Read full profile

    Fundamentals

    Net revenue
    €1.90B
    Gross margin
    96.6%
    EBIT
    €596.82M
    EBIT margin
    31.4%
    Net income
    €513.73M
    Net margin
    27.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.23B +17.2% €676.36M +31.7%
    €2.56B +14.9% €875.78M +29.5%
    €2.79B +8.9% €1.05B +20.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 15M $547.31M -472K Sell
    Ray Dalio 8.3K $306.99K -9K Sell

    Earnings Calls

    Latest earnings call: February 6, 2024 (Q4 2023)

    Add to watchlist

    Notifications